Kymera Therapeutics to unveil mid‑stage eczema trial data, aiming to challenge Dupixent

Kymera Therapeutics, a Massachusetts‑based biotech, is set to release data from its mid‑stage clinical trial of KT‑621 in eczema before the end of 2026. The trial results are being closely watched as the company hopes to position the oral therapy as a competitor to Sanofi‑Regeneron’s Dupixent, the current market leader in immunology and inflammatory disorders.

Dupixent generates tens of billions in annual revenue and treats over a million patients with eczema, asthma and COPD. Analysts at Jefferies have described the upcoming Kymera readout as one of the most impactful immunology and inflammatory (I&I) data releases of the year.

The outcome of the trial could have significant implications for Kymera’s market prospects, its pipeline of immunology drugs, and the broader competitive landscape for eczema treatments.

Investors and clinicians alike are awaiting the results, which may shape treatment options for the millions of people living with eczema worldwide.